{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:27:49Z","timestamp":1791520069171,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To verify whether myo-inositol plus \u03b1-lactalbumin may reduce insulin resistance and excessive fetal growth in women with gestational diabetes mellitus. In a 12-month period, 120 women with a diagnosis of gestational diabetes mellitus were consecutively enrolled with an allocation of 1:1 in each group and randomly treated with myo-inositol plus \u03b1-lactalbumin plus folic acid (treated group) or folic acid (control group) for 2\u00a0months. Primary outcome was the variation of insulin resistance through the study evaluated by HOMA-IR. Secondary outcome was the evaluation, through the study, of fetal growth by ultrasound measurements of abdominal circumference centiles and estimated fat thickness. Some clinical outcomes were also considered. After 2\u00a0months, in the treated group, a significant reduction in insulin resistance (HOMA values 3.1\u2009\u00b1\u20091.4 vs 6.1\u2009\u00b1\u20093.4, p\u2009=\u20090.0002) and fetal growth was shown (Abdominal circumference centiles 54.9\u2009\u00b1\u200923.5 vs 67.5\u2009\u00b1\u200922.6, P\u2009=\u20090.006). Among clinical outcomes, a significant decrease in the rate of women who needed insulin (6.7% vs 20.3%, p\u2009=\u20090.03) and of pre-term birth (0 vs 15.2%, p\u2009=\u20090.007) was evidenced. A combination of myo-inositol and \u03b1-lactalbumin may reduce insulin resistance and excessive fetal growth.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Clinical trial registration<\/jats:bold>\n                    : ClinicalTrials.gov,\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                    , NCT 03763669, first posted date 04\/12\/2018; last posted date December 06\/12\/2018.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-88329-x","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T06:12:30Z","timestamp":1619158350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Myoinositol plus \u03b1-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4655-5071","authenticated-orcid":false,"given":"Rosario","family":"D\u2019Anna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Loddo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Giunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Di Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"issue":"suppl 1","key":"88329_CR1","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.2337\/dc20-S002","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. Classification and diagnosis of diabetes. Standard of medical care in diabetes. Diabetes Care 43(suppl 1), S14\u2013S31 (2020).","journal-title":"Diabetes Care"},{"issue":"1","key":"88329_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12884-019-2185-y","volume":"19","author":"L Gilbert","year":"2019","unstructured":"Gilbert, L. et al. How diet, physical activity and psychosocial well-being interact in women with gestational diabetes mellitus: An integrative review. BMC Pregnancy Childbirth. 19(1), 60. https:\/\/doi.org\/10.1186\/s12884-019-2185-y (2019).","journal-title":"BMC Pregnancy Childbirth."},{"key":"88329_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.7326\/0003-4819-159-2-201307160-00661","volume":"159","author":"L Hartling","year":"2013","unstructured":"Hartling, L. et al. Benefit and harms of treating gestational diabetes mellitus: A systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. Ann. Intern. Med. 159, 123\u2013129 (2013).","journal-title":"Ann. Intern. Med."},{"key":"88329_CR4","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/j.1464-5491.2011.03284.x","volume":"28","author":"F Corrado","year":"2011","unstructured":"Corrado, F. et al. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet. Med. 28, 972\u2013975 (2011).","journal-title":"Diabet. Med."},{"key":"88329_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.diabet.2016.01.005","volume":"42","author":"V Lubin","year":"2016","unstructured":"Lubin, V., Shojai, R., Darmon, P. & Cosson, E. A pilot study of gestational diabetes mellitus not controlled by diet alone: First line medical treatment with myoinositol may limit the need for insulin. Diabetes Metab. 42, 192\u2013195 (2016).","journal-title":"Diabetes Metab."},{"key":"88329_CR6","doi-asserted-by":"publisher","first-page":"300.e1","DOI":"10.1016\/j.ajog.2018.05.018","volume":"219","author":"A Santamaria","year":"2018","unstructured":"Santamaria, A. et al. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: A secondary analysis from 3 RCTs. Am. J. Obstet. Gynecol. 219, 300.e1-300.e6 (2018).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"88329_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2337\/diacare.13.3.244","volume":"13","author":"AR Saltiel","year":"1990","unstructured":"Saltiel, A. R. Second messengers of insulin action. Diabetes Care 13, 244\u2013256 (1990).","journal-title":"Diabetes Care"},{"key":"88329_CR8","doi-asserted-by":"publisher","first-page":"255274","DOI":"10.1080\/17425255.2020.1737675","volume":"16","author":"F Facchinetti","year":"2020","unstructured":"Facchinetti, F. et al. Experts\u2019 opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: A further help for human reproduction and beyond. Expert Opin. Drug Metab. Toxicol. 16, 255274. https:\/\/doi.org\/10.1080\/17425255.2020.1737675 (2020).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"88329_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13048-018-0411-2","volume":"11","author":"M Montanino Oliva","year":"2018","unstructured":"Montanino Oliva, M., Buonomo, G., Calcagno, M. & Unfer, V. Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. J. Ovarian Res. 11, 38. https:\/\/doi.org\/10.1186\/s13048-018-0411-2 (2018).","journal-title":"J. Ovarian Res."},{"key":"88329_CR10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.2337\/dc10-0719","volume":"33","author":"BE Metzger","year":"2010","unstructured":"Metzger, B. E. et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycaemia in pregnancy. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. Diabetes Care 33, 676\u2013682 (2010).","journal-title":"Diabetes Care"},{"key":"88329_CR11","unstructured":"\u201cIstituto Superiore di Sanit\u00e0,\u201d Linee Guida per la gravidanza fisiologica. http:\/\/www.snlg-iss.it\/cms\/files\/LG_ Gravidanza.pdf. Retrieved Sept 2011."},{"issue":"1","key":"88329_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12916-018-1191-7","volume":"16","author":"JS Brand","year":"2018","unstructured":"Brand, J. S. et al. Gestational diabetes and ultrasound assessed fetal growth in South Asian and White European women: Findings from a prospective pregnancy cohort. BMC Med. 16(1), 203. https:\/\/doi.org\/10.1186\/s12916-018-1191-7 (2018).","journal-title":"BMC Med."},{"key":"88329_CR13","doi-asserted-by":"publisher","first-page":"e1002220","DOI":"10.1371\/journal.pmed.1002220","volume":"14","author":"T Kiserud","year":"2017","unstructured":"Kiserud, T. et al. The World Health Organization fetal growth charts: A multinational longitudinal study of ultrasound biometric measurements and estimated fetal weight. PLoS Med. 14, e1002220. https:\/\/doi.org\/10.1371\/journal.pmed.1002220 (2017).","journal-title":"PLoS Med."},{"key":"88329_CR14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/uog.926","volume":"22","author":"G Larciprete","year":"2003","unstructured":"Larciprete, G. et al. Fetal subcutaneous tissue thickness (SCTT) in healthy and gestational diabetic pregnancies. Ultrasound Obstet. Gynecol. 22, 591\u2013597 (2003).","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"88329_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/MPG.0b013e3181da213e","volume":"51","author":"E Bertino","year":"2010","unstructured":"Bertino, E. et al. Neonatal anthropometric charts: The Italian neonatal study compared with other European studies. J. Pediatr. Gastroenter. Nutr. 51, 353\u2013361 (2010).","journal-title":"J. Pediatr. Gastroenter. Nutr."},{"key":"88329_CR16","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.biochi.2013.05.011","volume":"95","author":"ML Croze","year":"2013","unstructured":"Croze, M. L. & Soulage, C. O. Potential role and therapeutic interest of myo-inositol in metabolic diseases. Biochimie 95, 1811\u20131827 (2013).","journal-title":"Biochimie"},{"key":"88329_CR17","first-page":"6567","volume":"22","author":"B Pintaudi","year":"2018","unstructured":"Pintaudi, B. et al. Effects of myo-inositol on glucose variability in women with gestational diabetes. Eur. Rev. Med. Pharmacol. Sci. 22, 6567\u20136572 (2018).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"88329_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9132052","author":"B Pintaudi","year":"2016","unstructured":"Pintaudi, B., Di Vieste, G. & Bonomo, M. The effectiveness of myo-inositol and D-chiro-inositol treatment in type 2 diabetes. Int. J. Endocrinol. https:\/\/doi.org\/10.1155\/2016\/9132052 (2016).","journal-title":"Int. J. Endocrinol."},{"key":"88329_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1056\/NEJM199008093230603","volume":"323","author":"AS Kennington","year":"1990","unstructured":"Kennington, A. S. et al. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 323, 373\u2013378 (1990).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41598-021-88329-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41598-021-88329-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41598-021-88329-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:30:54Z","timestamp":1684607454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88329-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["88329"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88329-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"assertion":[{"value":"7 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8866"}}